- Home
- DOYU vs TNGX Comparison
DOYU vs TNGX Comparison
Compare DOYU & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- TNGX
- Stock Information
- Founded
- DOYU 2014
- TNGX 2014
- Country
- DOYU China
- TNGX United States
- Employees
- DOYU N/A
- TNGX N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- TNGX Health Care
- Exchange
- DOYU Nasdaq
- TNGX Nasdaq
- Market Cap
- DOYU 278.1M
- TNGX 317.4M
- IPO Year
- DOYU 2019
- TNGX N/A
- Fundamental
- Price
- DOYU $6.31
- TNGX $1.29
- Analyst Decision
- DOYU Sell
- TNGX Strong Buy
- Analyst Count
- DOYU 3
- TNGX 7
- Target Price
- DOYU $10.33
- TNGX $12.33
- AVG Volume (30 Days)
- DOYU 149.3K
- TNGX 756.3K
- Earning Date
- DOYU 06-04-2025
- TNGX 05-07-2025
- Dividend Yield
- DOYU 311.11%
- TNGX N/A
- EPS Growth
- DOYU N/A
- TNGX N/A
- EPS
- DOYU N/A
- TNGX N/A
- Revenue
- DOYU $585,116,657.00
- TNGX $42,069,000.00
- Revenue This Year
- DOYU N/A
- TNGX N/A
- Revenue Next Year
- DOYU N/A
- TNGX N/A
- P/E Ratio
- DOYU N/A
- TNGX N/A
- Revenue Growth
- DOYU N/A
- TNGX 15.17
- 52 Week Low
- DOYU $5.68
- TNGX $1.11
- 52 Week High
- DOYU $20.17
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- DOYU 35.12
- TNGX 37.63
- Support Level
- DOYU $5.96
- TNGX $1.25
- Resistance Level
- DOYU $6.68
- TNGX $1.44
- Average True Range (ATR)
- DOYU 0.46
- TNGX 0.15
- MACD
- DOYU 0.10
- TNGX 0.03
- Stochastic Oscillator
- DOYU 31.12
- TNGX 45.00
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.